

# ONCOLOGY AND BIOMARKERS SUMMIT

November 27-28, 2017 | Atlanta, USA

## Innovative approaches in metabolomics for understanding drug resistance in breast cancer

Umber Saeed

Dow University Of Health and Sciences, Pakistan

**B**reast cancer is one of the leading cause of death worldwide. In Pakistan, prevalence of this ailment is highest amongst all types of cancer i.e. 38.5%. Among various treatments available to overcome cancer, chemotherapy is the one used most widely most oftenly a combination of two or more medicines will be used as chemotherapy treatment for breast cancer. But in Chemotherapy, major clinical setback is drug resistance. Metabolomics is an emerging field that utilizes information of cellular biochemistry for the early detection, diagnosis and establishment of predictive biomarkers of breast cancer. Currently, metabolomics is use to evaluate a much comprehensive picture of tumor development and growth This review highlights potential metabolomics applications towards developing a more personalized and tailored chemotherapy treatment. The methodology is based on inclusion exclusion criteria. Literature survey and questionnaire were included while clinical trials was excluded. This report provides a review of 12 articles out which few were excluded. The objective

was to explore: Early breast cancer detection; Increasing life expectancy of cancer patients; Mechanisms for breast cancer drug resistance; Chemotherapy in breast cancer and its success rate and Side effects of chemotherapy in breast cancer. According to the survey the average response rate of a cancer drug is the lowest at 21%, suggesting that 79% of patients with cancer are over-dosed. While according to an international study, 40%–50% of breast tumors will display acquired resistance. When specific therapies are chosen on the basis of a patient’s metabolomics profile, it will give rise to customized medicine and personalized tailored treatment. Using high throughput information using metabolomics to clinical diagnosis and treatment can help accelerate the patient safety, quality of life and survival rate by identifying pathways involved in drug resistance. Metabolomics is future of anti-cancer pharmacology, following “the right drug for the right patient at the right time” can offer safety, quality and effectiveness of anti-cancer treatment.

e: mahi.umber@gmail.com